Business Description
Denali Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US24823R1059
Total Employee Number:
507Compare
Compare
Traded in other countries / regions
DNLI.USA4DN.GermanyD2NL34.Brazil Index Membership
Russell 2000Russell 3000 IPO Date
2017-12-08Description
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 22.06 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.06 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -6 | |||||
3-Year EPS without NRI Growth Rate | -4.5 | |||||
3-Year FCF Growth Rate | -5.3 | |||||
3-Year Book Growth Rate | -5.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 14.51 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.1 | |||||
9-Day RSI | 27.05 | |||||
14-Day RSI | 35.4 | |||||
3-1 Month Momentum % | 20.01 | |||||
6-1 Month Momentum % | 18.65 | |||||
12-1 Month Momentum % | 63.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.37 | |||||
Quick Ratio | 8.32 | |||||
Cash Ratio | 7.89 | |||||
Days Inventory | 16244.46 | |||||
Days Sales Outstanding | 309.1 | |||||
Days Payable | 57384.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.7 | |||||
Shareholder Yield % | 0.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 97.42 | |||||
Operating Margin % | -15058.19 | |||||
Net Margin % | -14191.2 | |||||
EBITDA Margin % | -14617.31 | |||||
FCF Margin % | -12937.21 | |||||
OCF Margin % | -12043.29 | |||||
ROE % | -54.08 | |||||
ROA % | -44.16 | |||||
ROIC % | -177.64 | |||||
3-Year ROIIC % | 225.04 | |||||
ROC (Joel Greenblatt) % | -449.3 | |||||
ROCE % | -51.09 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1172.63 | |||||
PB Ratio | 4.26 | |||||
Price-to-Tangible-Book | 4.45 | |||||
EV-to-EBIT | -5.31 | |||||
EV-to-Forward-EBIT | 66.13 | |||||
EV-to-EBITDA | -5.47 | |||||
EV-to-Forward-EBITDA | 52.31 | |||||
EV-to-Revenue | 799.98 | |||||
EV-to-Forward-Revenue | 19.98 | |||||
EV-to-FCF | -6.18 | |||||
| Price-to-Net-Current-Asset-Value | 8.25 | |||||
| Price-to-Net-Cash | 9.17 | |||||
Earnings Yield (Greenblatt) % | -18.83 | |||||
FCF Yield % | -13.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DNLI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Denali Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.604 | ||
| EPS (TTM) ($) | -2.84 | ||
| Beta | 1.4051 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 51.12 | ||
| 14-Day RSI | 35.4 | ||
| 14-Day ATR ($) | 0.908482 | ||
| 20-Day SMA ($) | 24.28625 | ||
| 12-1 Month Momentum % | 63.42 | ||
| 52-Week Range ($) | 12.58 - 27.3 | ||
| Shares Outstanding (Mil) | 159.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Denali Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Denali Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 173 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 173 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 61 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 24.42 (+0.54%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 24.42 (+0.54%) | ||
| General meeting for 2026 | 2026-06-03 10:00 | 19.35 (-3.06%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 20.41 (+6.19%) | ||
| Annual report for 2025 | 2026-02-26 | 22.29 (+3.19%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 22.29 (+3.19%) | ||
| Guidance call for 2026 | 2026-02-05 12:30 | 21.28 (-3.18%) |
Show
Entries
Denali Therapeutics Inc Frequently Asked Questions
What is Denali Therapeutics Inc(DNLI)'s stock price today?
The current price of DNLI is $22.28. The 52 week high of DNLI is $27.30 and 52 week low is $12.58.
When is next earnings date of Denali Therapeutics Inc(DNLI)?
The next earnings date of Denali Therapeutics Inc(DNLI) is 2026-11-06 Est..
Does Denali Therapeutics Inc(DNLI) pay dividends? If so, how much?
Denali Therapeutics Inc(DNLI) does not pay dividend.
Guru Commentaries on NAS:DNLI
Speaker of the Management
Bullish
2026 Q2
ACATIS Investment report July 2026
What the manager wrote
Denali Therapeutics is a promising investment due to its innovative transport vehicle platform, which is essential for delivering enzymes or antibodies across the blood-brain barrier. This technology is crucial for treating conditions like Alzheimer's and Parkinson's disease. The company has already achieved a significant milestone with the approval of a medication for Hunter Syndrome. The market has overlooked Denali, despite its potential to address major health challenges associated with an aging population.
Press Release
Articles on Denali Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers